Cargando…
In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma
SIMPLE SUMMARY: Canine mammary carcinomas (CMC) are associated with poor clinical outcomes and high mortality. Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis and tumor progression in many solid tumors, including mammary carcinomas. The goal of this work was to establish...
Autores principales: | Cardama, Georgina A., Bucci, Paula L., Lemos, Jesús S., Llavona, Candela, Benavente, Micaela A., Hellmén, Eva, Fara, María Laura, Medrano, Eduardo, Spitzer, Eduardo, Demarco, Ignacio A., Sabella, Patricia, Garona, Juan, Alonso, Daniel F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417262/ https://www.ncbi.nlm.nih.gov/pubmed/37570315 http://dx.doi.org/10.3390/ani13152507 |
Ejemplares similares
-
Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab
por: Miguel‐Lillo, B., et al.
Publicado: (2023) -
A randomized, double‐blind, single‐dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab
por: Schwabe, C., et al.
Publicado: (2023) -
A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers
por: Sinn, Angela, et al.
Publicado: (2021) -
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
por: Trukhin, Dmytro, et al.
Publicado: (2021) -
A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers
por: Eto, Takashi, et al.
Publicado: (2021)